Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

ALMS vs DBVT vs ABBV vs PRGO

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
ALMS
Alumis Inc. Common Stock

Biotechnology

HealthcareNASDAQ • US
Market Cap$2.79B
5Y Perf.+78.6%
DBVT
DBV Technologies S.A.

Biotechnology

HealthcareNASDAQ • FR
Market Cap$1712.35T
5Y Perf.+299.8%
ABBV
AbbVie Inc.

Drug Manufacturers - General

HealthcareNYSE • US
Market Cap$358.42B
5Y Perf.+18.1%
PRGO
Perrigo Company plc

Drug Manufacturers - Specialty & Generic

HealthcareNYSE • IE
Market Cap$1.61B
5Y Perf.-54.4%

ALMS vs DBVT vs ABBV vs PRGO — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
ALMS logoALMS
DBVT logoDBVT
ABBV logoABBV
PRGO logoPRGO
IndustryBiotechnologyBiotechnologyDrug Manufacturers - GeneralDrug Manufacturers - Specialty & Generic
Market Cap$2.79B$1712.35T$358.42B$1.61B
Revenue (TTM)$22M$0.00$61.16B$4.18B
Net Income (TTM)$-245M$-168M$4.23B$-1.82B
Gross Margin96.3%70.2%34.2%
Operating Margin-20.6%26.7%-4.1%
Forward P/E14.3x5.6x
Total Debt$37M$22M$69.07B$3.97B
Cash & Equiv.$90M$194M$5.23B$532M

ALMS vs DBVT vs ABBV vs PRGOLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

ALMS
DBVT
ABBV
PRGO
StockJun 24May 26Return
Alumis Inc. Common … (ALMS)100178.6+78.6%
DBV Technologies S.… (DBVT)100399.8+299.8%
AbbVie Inc. (ABBV)100118.1+18.1%
Perrigo Company plc (PRGO)10045.6-54.4%

Price return only. Dividends and distributions are not included.

Quick Verdict: ALMS vs DBVT vs ABBV vs PRGO

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: ABBV leads in 5 of 7 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Alumis Inc. Common Stock is the stronger pick specifically for recent price momentum and sentiment. PRGO also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
ALMS
Alumis Inc. Common Stock
The Defensive Pick

ALMS is the #2 pick in this set and the best alternative if sleep-well-at-night is your priority.

  • Lower volatility, beta 1.77, Low D/E 12.3%, current ratio 4.34x
  • +396.0% vs PRGO's -51.2%
Best for: sleep-well-at-night
DBVT
DBV Technologies S.A.
The Secondary Option

DBVT lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: healthcare exposure
ABBV
AbbVie Inc.
The Growth Play

ABBV carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.

  • Rev growth 8.6%, EPS growth -0.8%, 3Y rev CAGR 1.8%
  • 295.5% 10Y total return vs ALMS's 78.6%
  • 8.6% revenue growth vs DBVT's -100.0%
  • 6.9% margin vs ALMS's -11.1%
Best for: growth exposure and long-term compounding
PRGO
Perrigo Company plc
The Income Pick

PRGO is the clearest fit if your priority is income & stability and defensive.

  • Dividend streak 10 yrs, beta 1.18, yield 9.8%
  • Beta 1.18, yield 9.8%, current ratio 2.76x
  • Lower P/E (5.6x vs 14.3x)
Best for: income & stability and defensive
See the full category breakdown
CategoryWinnerWhy
GrowthABBV logoABBV8.6% revenue growth vs DBVT's -100.0%
ValuePRGO logoPRGOLower P/E (5.6x vs 14.3x)
Quality / MarginsABBV logoABBV6.9% margin vs ALMS's -11.1%
Stability / SafetyABBV logoABBVBeta 0.34 vs ALMS's 1.77
DividendsABBV logoABBV3.2% yield, 13-year raise streak, vs PRGO's 9.8%, (2 stocks pay no dividend)
Momentum (1Y)ALMS logoALMS+396.0% vs PRGO's -51.2%
Efficiency (ROA)ABBV logoABBV3.1% ROA vs DBVT's -89.0%

ALMS vs DBVT vs ABBV vs PRGO — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

ALMSAlumis Inc. Common Stock
FY 2025
License
72.3%$17M
Collaboration Revenue
27.7%$7M
DBVTDBV Technologies S.A.

Segment breakdown not available.

ABBVAbbVie Inc.
FY 2025
SKYRIZI
30.2%$17.6B
RINVOQ
14.3%$8.3B
H U M I R A
7.8%$4.5B
Botox Therapeutic
6.5%$3.8B
Vraylar
6.2%$3.6B
Imbruvica
4.9%$2.9B
VENCLEXTA
4.8%$2.8B
Other (14)
25.3%$14.7B
PRGOPerrigo Company plc
FY 2025
Consumer Self-Care Americas
60.8%$2.6B
Consumer Self-Care International
39.2%$1.7B

ALMS vs DBVT vs ABBV vs PRGO — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLABBVLAGGINGDBVT

Income & Cash Flow (Last 12 Months)

ABBV leads this category, winning 5 of 6 comparable metrics.

ABBV and DBVT operate at a comparable scale, with $61.2B and $0 in trailing revenue. ABBV is the more profitable business, keeping 6.9% of every revenue dollar as net income compared to ALMS's -11.1%. On growth, ABBV holds the edge at +10.0% YoY revenue growth, suggesting stronger near-term business momentum.

MetricALMS logoALMSAlumis Inc. Commo…DBVT logoDBVTDBV Technologies …ABBV logoABBVAbbVie Inc.PRGO logoPRGOPerrigo Company p…
RevenueTrailing 12 months$22M$0$61.2B$4.2B
EBITDAEarnings before interest/tax-$453M-$112M$24.5B$58M
Net IncomeAfter-tax profit-$245M-$168M$4.2B-$1.8B
Free Cash FlowCash after capex-$373M-$151M$18.7B$108M
Gross MarginGross profit ÷ Revenue+96.3%+70.2%+34.2%
Operating MarginEBIT ÷ Revenue-20.6%+26.7%-4.1%
Net MarginNet income ÷ Revenue-11.1%+6.9%-43.5%
FCF MarginFCF ÷ Revenue-16.9%+30.6%+2.6%
Rev. Growth (YoY)Latest quarter vs prior year+10.0%-7.2%
EPS Growth (YoY)Latest quarter vs prior year+38.7%+91.5%+57.4%-56.4%
ABBV leads this category, winning 5 of 6 comparable metrics.

Valuation Metrics

PRGO leads this category, winning 5 of 6 comparable metrics.

On an enterprise value basis, PRGO's 7.4x EV/EBITDA is more attractive than ABBV's 15.0x.

MetricALMS logoALMSAlumis Inc. Commo…DBVT logoDBVTDBV Technologies …ABBV logoABBVAbbVie Inc.PRGO logoPRGOPerrigo Company p…
Market CapShares × price$2.8B$1712.35T$358.4B$1.6B
Enterprise ValueMkt cap + debt − cash$2.7B$1712.35T$422.3B$5.1B
Trailing P/EPrice ÷ TTM EPS-8.31x-0.76x85.50x-1.14x
Forward P/EPrice ÷ next-FY EPS est.14.28x5.56x
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple14.96x7.42x
Price / SalesMarket cap ÷ Revenue116.09x5.86x0.38x
Price / BookPrice ÷ Book value/share67.05x0.66x0.55x
Price / FCFMarket cap ÷ FCF20.12x11.12x
PRGO leads this category, winning 5 of 6 comparable metrics.

Profitability & Efficiency

ABBV leads this category, winning 6 of 9 comparable metrics.

ABBV delivers a 62.1% return on equity — every $100 of shareholder capital generates $62 in annual profit, vs $-130 for DBVT. ALMS carries lower financial leverage with a 0.12x debt-to-equity ratio, signaling a more conservative balance sheet compared to PRGO's 1.35x. On the Piotroski fundamental quality scale (0–9), ABBV scores 6/9 vs ALMS's 3/9, reflecting solid financial health.

MetricALMS logoALMSAlumis Inc. Commo…DBVT logoDBVTDBV Technologies …ABBV logoABBVAbbVie Inc.PRGO logoPRGOPerrigo Company p…
ROE (TTM)Return on equity-75.5%-130.2%+62.1%-50.7%
ROA (TTM)Return on assets-57.6%-89.0%+3.1%-19.8%
ROICReturn on invested capital-184.1%+23.9%+3.7%
ROCEReturn on capital employed-144.4%-145.7%+21.5%+4.3%
Piotroski ScoreFundamental quality 0–93464
Debt / EquityFinancial leverage0.12x0.13x1.35x
Net DebtTotal debt minus cash-$53M-$172M$63.8B$3.4B
Cash & Equiv.Liquid assets$90M$194M$5.2B$532M
Total DebtShort + long-term debt$37M$22M$69.1B$4.0B
Interest CoverageEBIT ÷ Interest expense-189.82x3.28x-7.20x
ABBV leads this category, winning 6 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

ALMS leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in ABBV five years ago would be worth $20,131 today (with dividends reinvested), compared to $3,090 for DBVT. Over the past 12 months, ALMS leads with a +396.0% total return vs PRGO's -51.2%. The 3-year compound annual growth rate (CAGR) favors ALMS at 21.3% vs PRGO's -25.2% — a key indicator of consistent wealth creation.

MetricALMS logoALMSAlumis Inc. Commo…DBVT logoDBVTDBV Technologies …ABBV logoABBVAbbVie Inc.PRGO logoPRGOPerrigo Company p…
YTD ReturnYear-to-date+165.3%+4.9%-10.1%-13.5%
1-Year ReturnPast 12 months+396.0%+110.4%+11.3%-51.2%
3-Year ReturnCumulative with dividends+78.6%+19.7%+50.4%-58.1%
5-Year ReturnCumulative with dividends+78.6%-69.1%+101.3%-60.1%
10-Year ReturnCumulative with dividends+78.6%-87.0%+295.5%-77.7%
CAGR (3Y)Annualised 3-year return+21.3%+6.2%+14.6%-25.2%
ALMS leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

ABBV leads this category, winning 2 of 2 comparable metrics.

ABBV is the less volatile stock with a 0.34 beta — it tends to amplify market swings less than ALMS's 1.77 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ABBV currently trades 82.8% from its 52-week high vs PRGO's 41.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricALMS logoALMSAlumis Inc. Commo…DBVT logoDBVTDBV Technologies …ABBV logoABBVAbbVie Inc.PRGO logoPRGOPerrigo Company p…
Beta (5Y)Sensitivity to S&P 5001.77x1.26x0.34x1.18x
52-Week HighHighest price in past year$30.60$26.18$244.81$28.44
52-Week LowLowest price in past year$2.76$7.53$176.57$9.23
% of 52W HighCurrent price vs 52-week peak+77.6%+76.3%+82.8%+41.2%
RSI (14)Momentum oscillator 0–10054.348.146.860.9
Avg Volume (50D)Average daily shares traded1.4M252K5.8M3.4M
ABBV leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Evenly matched — ABBV and PRGO each lead in 1 of 2 comparable metrics.

Analyst consensus: ALMS as "Buy", DBVT as "Buy", ABBV as "Buy", PRGO as "Hold". Consensus price targets imply 131.8% upside for DBVT (target: $46) vs 26.6% for ABBV (target: $257). For income investors, PRGO offers the higher dividend yield at 9.81% vs ABBV's 3.24%.

MetricALMS logoALMSAlumis Inc. Commo…DBVT logoDBVTDBV Technologies …ABBV logoABBVAbbVie Inc.PRGO logoPRGOPerrigo Company p…
Analyst RatingConsensus buy/hold/sellBuyBuyBuyHold
Price TargetConsensus 12-month target$38.44$46.33$256.64$20.00
# AnalystsCovering analysts8154136
Dividend YieldAnnual dividend ÷ price+3.2%+9.8%
Dividend StreakConsecutive years of raises01310
Dividend / ShareAnnual DPS$6.57$1.15
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%+0.3%0.0%
Evenly matched — ABBV and PRGO each lead in 1 of 2 comparable metrics.
Key Takeaway

ABBV leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). PRGO leads in 1 (Valuation Metrics). 1 tied.

Best OverallAbbVie Inc. (ABBV)Leads 3 of 6 categories
Loading custom metrics...

ALMS vs DBVT vs ABBV vs PRGO: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is ALMS or DBVT or ABBV or PRGO a better buy right now?

For growth investors, AbbVie Inc.

(ABBV) is the stronger pick with 8. 6% revenue growth year-over-year, versus -2. 8% for Perrigo Company plc (PRGO). AbbVie Inc. (ABBV) offers the better valuation at 85. 5x trailing P/E (14. 3x forward), making it the more compelling value choice. Analysts rate Alumis Inc. Common Stock (ALMS) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — ALMS or DBVT or ABBV or PRGO?

On forward P/E, Perrigo Company plc is actually cheaper at 5.

6x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — ALMS or DBVT or ABBV or PRGO?

Over the past 5 years, AbbVie Inc.

(ABBV) delivered a total return of +101. 3%, compared to -69. 1% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: ABBV returned +295. 5% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — ALMS or DBVT or ABBV or PRGO?

By beta (market sensitivity over 5 years), AbbVie Inc.

(ABBV) is the lower-risk stock at 0. 34β versus Alumis Inc. Common Stock's 1. 77β — meaning ALMS is approximately 423% more volatile than ABBV relative to the S&P 500. On balance sheet safety, Alumis Inc. Common Stock (ALMS) carries a lower debt/equity ratio of 12% versus 135% for Perrigo Company plc — giving it more financial flexibility in a downturn.

05

Which is growing faster — ALMS or DBVT or ABBV or PRGO?

By revenue growth (latest reported year), AbbVie Inc.

(ABBV) is pulling ahead at 8. 6% versus -2. 8% for Perrigo Company plc (PRGO). On earnings-per-share growth, the picture is similar: Alumis Inc. Common Stock grew EPS 72. 4% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, ABBV leads at 1. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — ALMS or DBVT or ABBV or PRGO?

AbbVie Inc.

(ABBV) is the more profitable company, earning 6. 9% net margin versus -1011. 7% for Alumis Inc. Common Stock — meaning it keeps 6. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ABBV leads at 32. 8% versus -1886. 9% for ALMS. At the gross margin level — before operating expenses — ALMS leads at 96. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is ALMS or DBVT or ABBV or PRGO more undervalued right now?

On forward earnings alone, Perrigo Company plc (PRGO) trades at 5.

6x forward P/E versus 14. 3x for AbbVie Inc. — 8. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DBVT: 131. 8% to $46. 33.

08

Which pays a better dividend — ALMS or DBVT or ABBV or PRGO?

In this comparison, PRGO (9.

8% yield), ABBV (3. 2% yield) pay a dividend. ALMS, DBVT do not pay a meaningful dividend and should not be held primarily for income.

09

Is ALMS or DBVT or ABBV or PRGO better for a retirement portfolio?

For long-horizon retirement investors, AbbVie Inc.

(ABBV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 34), 3. 2% yield, +295. 5% 10Y return). Alumis Inc. Common Stock (ALMS) carries a higher beta of 1. 77 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ABBV: +295. 5%, ALMS: +78. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between ALMS and DBVT and ABBV and PRGO?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ALMS is a small-cap quality compounder stock; DBVT is a mega-cap quality compounder stock; ABBV is a large-cap income-oriented stock; PRGO is a small-cap income-oriented stock. ABBV, PRGO pay a dividend while ALMS, DBVT do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

ALMS

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 57%
Run This Screen
Stocks Like

DBVT

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

ABBV

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 5%
Run This Screen
Stocks Like

PRGO

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 20%
  • Dividend Yield > 3.9%
Run This Screen

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.